What you’ll learn on this page:
- Infilbray is the first and only therapy to demonstrate neurologic improvement for patients with Gaucher disease type 31
- Infilbray crosses the blood-brain barrier and remains CNS active, reducing GL-1 and lyso-GL-11
- Infilbray is administered conveniently with once-daily oral dosing that can be taken with or without food1
Infilbray is the first and only therapy to deliver a neurologic breakthrough in Gaucher disease type 31,2
Approved to treat neurologic manifestations in GD3 patients weighing ≥15 kg.1

Demonstrated neurologic improvement1

Crosses the blood-brain barrier1
Remains CNS active, reducing GL-1 and lyso-GL-1

Convenient once-daily oral dosing1
Can be taken with or without food
Infilbray crosses the blood-brain barrier and directly targets the underlying cause of neurologic symptoms1,3
Crosses the blood-brain barrier1
Infilbray can access the brain, enabling it to provide activity in the CNS.
Reduces GL-1 and lyso-GL-11
Infilbray is a glucosylceramide synthase inhibitor (GCSi) that reduces the synthesis of GL-1 and subsequently lyso-GL-1.
Frequently asked questions
Interested in learning more?
CNS=central nervous system; CSF=cerebrospinal fluid; ERT=enzyme replacement therapy; GCS=glucosylceramide synthase; GCSi=glucosylceramide synthase inhibitor; GD3=Gaucher disease type 3; GL-1=glucosylceramide; LS=least squares; lyso-GL-1=glucosylsphingosine; OLS=ordinary least squares; RBANS=Repeatable Battery for the Assessment of Neuropsychological Status; SARA=Scale for the Assessment and Rating of Ataxia; SE=standard error; SRT=substrate reduction therapy.
Relevant pages to view:
Indication
References: 1. Infilbray (venglustat). Prescribing information. Genzyme Corporation, Cambridge, MA. 2. Sanofi. Press release: Sanofi’s venglustat earns breakthrough therapy designation in the US for type 3 Gaucher disease. Accessed October 5, 2026. https://www.sanofi.com/en/media-room/press-releases/2026/2026-03-18-06-00-00-3257888 3. Grabowski GA et al. The Online Metabolic and Molecular Bases of Inherited Disease. Accessed August 7, 2026. https://ommbid.mhmedical.com/content.aspx?bookid=2709§ionid=225546056 4. Schiffmann R et al. J Inherit Metab Dis. 2020;43(5):1056-1059. 5. Mistry P et al. Poster presented at: WORLDSymposium; February 2-6, 2026; San Diego, CA.
